Tscan Therapeutics, Inc. (TCRX) Stock Price & Analysis
Tscan Therapeutics, Inc. (TCRX) fell 2.86% to USD 0.97 as of June 10, 2026 at 02:35 UTC, according to Nexqual real-time market data.
TCRX last closed at USD 0.99; the session ranged USD 0.96–1.03 on volume of 326,780 shares. Market capitalization is $63.10M, with a 52-week range of USD 0.88–2.57 (NGM). Source: Nexqual, June 10, 2026 at 02:35 UTC.
Key Statistics (as of June 10, 2026 at 02:35 UTC)
| Price | USD 0.97 |
|---|---|
| Change | ▼ 2.86% (down) |
| Previous Close | USD 0.99 |
| Open | USD 1.01 |
| Day Range | USD 0.96 – 1.03 |
| 52-Week Range | USD 0.88 – 2.57 |
| Volume | 326,780 shares |
| Market Cap | $63.10M |
| Exchange | NGM |
Technical Analysis (TCRX)
Nexqual's technical model rates TCRX "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:35 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.25 (neutral) |
| vs SMA50 | Below (USD 1.1) |
| MACD | -0.04 (negative) |
Analyst Ratings (TCRX)
Wall Street analysts rate TCRX "None" based on 4 analysts, with a mean price target of USD 6 (range USD 5–7), per Nexqual as of June 10, 2026 at 02:35 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 6 |
| High Target | USD 7 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 5 / 1 / 0 |
Earnings (TCRX)
| EPS Estimate | USD -0.21 |
|---|---|
| Revenue Estimate | $2.50M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.22 vs est -0.17 ▼ miss |
| 2025-12-31 | USD -0.18 vs est -0.28 ▲ beat |
| 2025-09-30 | USD -0.28 vs est -0.33 ▲ beat |
| 2025-06-30 | USD -0.28 vs est -0.32 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:35 UTC.
Financials & Fundamentals (TCRX)
| Total Revenue | $9.14M |
|---|---|
| Revenue Growth (YoY) | -54.80% |
| Gross Margin | +0.00% |
| Operating Margin | -2967.31% |
| Profit Margin | +0.00% |
| ROE | -80.95% |
| Debt / Equity | 95.48 |
| Current Ratio | 6.65 |
| Total Cash | $128.06M |
| Total Debt | $92.54M |
| Free Cash Flow | $-84.11M |
Source: Nexqual, June 10, 2026 at 02:35 UTC.
Financial Health Score (TCRX)
Nexqual rates Tscan Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:35 UTC.
| Growth | Strong — Revenue +267% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $128M cash vs $93M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$84M, burning cash |
| Efficiency | Critical — ROE -81%, ROA -29.6% |
Ownership (TCRX)
| Insider Ownership | +0.20% |
|---|---|
| Institutional Ownership | +59.50% |
| Shares Outstanding | 61.07M |
| Float | 55.39M |
| Short % of Float | +2.09% |
Source: Nexqual, June 10, 2026 at 02:35 UTC.
Leadership (TCRX)
Tscan Therapeutics, Inc. is led by Gavin MacBeath (age 55), CEO & Director, per Nexqual as of June 10, 2026 at 02:35 UTC.
| CEO & Director | Gavin MacBeath (age 55) |
|---|---|
| CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | Jason A. Amello (age 57) |
| Co-Founder & Chairman of Scientific Advisory Board | Stephen J. Elledge |
Major Backers & Investors (TCRX)
Notable institutional backers of Tscan Therapeutics, Inc. include Lynx1 Capital Management Lp, BVF Inc., Baker Bros. Advisors, LP, according to Nexqual as of June 10, 2026 at 02:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Lynx1 Capital Management Lp | 13.13% |
| BVF Inc. | 9.11% |
| Baker Bros. Advisors, LP | 4.56% |
| Millennium Management | 2.39% |
| Renaissance Technologies | 2.23% |
| Deer Management Co. LLC | 2.04% |
| Two Sigma Investments, LP | 1.98% |
| Aberdeen Group plc | 1.5% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.94% |
| BlackRock | 4.78% |
Source: Nexqual, June 10, 2026 at 02:35 UTC.
From Tscan Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- Our current proprietary pipeline is summarized in the figure below.         In addition to our proprietary pipeline programs noted above, we have also entered into collaborations with strategic partners for applications of our platform technologies.
- The term of the royalty agreement continues until expiration of the last applicable royalty term.   Manufacturing   We have built in-house cell therapy manufacturing capabilities as one of the key components of our platform.
- To provide an operationally flexible and cost-effective approach for our heme program, we have developed a manufacturing platform to genetically engineer T cells using a transposon/transposase system.
- Our non-viral vector delivery system allows us to include additional T cell enhancements in our product candidates.
Partnerships
- License and Collaboration Agreements Collaboration Agreement with Amgen   On May 8, 2023, we entered into a Research Collaboration and License Agreement with Amgen Inc. (Amgen), or the Amgen Agreement, to identify antigens recognized by T cells in patients with Crohn's disease utilizing our proprietary target discovery platform.
- To date, we have a research collaboration and license agreement with Amgen to identify the antigens recognized by T cells in patients with Crohn's disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ERAS | Erasca, Inc. | USD 13.41 | ▲ 12.03% |
| INAB | IN8bio, Inc. | USD 1.45 | ▲ 0% |
| ABOS | Acumen Pharmaceuticals, Inc. | USD 2.19 | ▲ 1.86% |
| HOWL | Werewolf Therapeutics, Inc. | USD 0.37 | ▼ 4.46% |
| IPSC | Century Therapeutics, Inc. | USD 2.21 | ▲ 3.76% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:35 UTC. This page is informational and not investment advice.